Entera Bio Ltd. (ENTX) Q4 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the Interrobio fourth quarter and year-end 2021 earnings call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the call over to Ramesh Ratan, Chief Financial Officer. Thank you. You may begin. Good morning and welcome to the call. Joining me on today's call are Scott Johns, our CEO, Arthur Santora, our chief medical officer, and Philip Schwartz, our founder and president of R&D. A press release announcing NTERRA's financial and operating results for the full year ended December 31, 2021, was issued this morning. For those of you who have not yet seen it, it's available on the investor section of our website, www.nterrabio.com. On our call this morning, we will share with you a business update and review of our financial results, which will be followed by a question and answer session. Before we begin our prepared remarks, I'd like to remind you that various statements we make during this call about the company's future results of operation and financial position, our importation of data from the recently completed phase two clinical trial of EB613, our business strategy, and plans and objectives for our future operations are considered forward-looking statements within the meaning of the federal securities laws. Our forward-looking statements are based upon current expectation that involve risks, changes in circumstances, assumptions, and uncertainties. Specifically, developments related to the COVID-19 pandemic continue to evolve and the extent to which the pandemic will impact...